Assess the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy using the HCM Risk Calculator from the AHA. Try it our for free now.

2024年5月8日 · Hypertrophic cardiomyopathy remains a common genetic heart disease reported in populations globally. Recommendations from the “2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy” have been updated with new evidence to guide clinicians.

2020年11月20日 · The proposed approach recognizes that spectrum and is inclusive of roles for cardiologists working outside of HCM centers, those working in primary HCM centers that offer many or most HCM-specific services, and those working at fully comprehensive HCM centers.

2025年2月27日 · High-intensity statin therapy is recommended for all patients with ACS, and with the option to initiate concurrent ezetimibe. A nonstatin lipid-lowering agent (eg, ezetimibe, evolocumab, alirocumab, inclisiran, bempedoic acid) is recommended for patients already on maximally tolerated statin who have a low-density lipoprotein cholesterol level …

The 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy (AHA/ACC/Multisociety HCM Guideline) provides guidance for clinicians on the management of patients with hypertrophic cardiomyopathy (HCM). 1 The guideline contains updated, evidence-based recommendations that build on those from the 2020 HCM ...

2024年5月29日 · The American Heart Association explains hypertrophic cardiomyopathy (HCM) including obstructive and nonobstructive HCM. Also learn symptoms, diagnosis and treatment for HCM.

2024年5月8日 · The following are key points to remember from the 2024 AHA/ACC/multisociety guideline for the management of hypertrophic cardiomyopathy (HCM): Patients with HCM should be engaged in shared decision making to develop a care plan.

hypertrophic cardiomyopathy (HCM) centers with appropriate expertise can be important to optimizing care for patients with HCM. Challenging treatment decisions—where reasonable alternatives exist, where the strength of recommendation is weak (eg, …

The 2024 AHA/ACC/Multisociety Hypertrophic Cardiomyopathy Guideline provides guidance for clinicians on the management of patients with HCM. The guideline contains updated, evidence-based recommendations that build on those from the 2020 HCM Guideline in the following areas: risk assessment of sudden cardiac death, exercise recommendation ...

2020年11月20日 · The following are key perspectives from the 2020 American Heart Association/American College of Cardiology (AHA/ACC) guideline for the management of patients with hypertrophic cardiomyopathy (HCM): Shared decision making is recommended for all aspects of HCM care including genetic testing, activity, lifestyle, and therapy choices.